MonoSol Rx Appoints Joseph Crusco Director of Business Development

WARREN, N.J., July 10, 2014 (GLOBE NEWSWIRE) -- MonoSol Rx, the developer of PharmFilm® drug delivery technology, today announced the appointment of Joseph Crusco to the position of Director, Business Development. Mr. Crusco will report to Dan Barber, Vice President of Business Development, and will be responsible for leading MonoSol Rx's business development activities including implementing the company's' licensing and strategic partnering strategy.

A. Mark Schobel, Chief Executive Officer of MonoSol Rx said, "We are pleased to welcome Joe to the MonoSol Rx team. He is an important strategic addition as we intensify our business development efforts to meet our near- and longer-term growth objectives. Joe is a highly accomplished, forward-thinking professional with a great deal of sales, business and commercial expertise. His strong product knowledge, background and relationships in the pharmaceutical, biotech and vaccine industries will be invaluable as we expand our business moving forward."

Prior to joining MonoSol Rx, Crusco was Senior Director at Unilife Corporation where he was responsible for identification, qualification and negotiation of commercial development opportunities for Unilife's injection system product Platform. Previously, Joe was the Marketing and Business Development Director at Datwyler Pharma Packaging, where he was responsible for developing strategies for Datwyler's strategic target markets (vaccines, diabetic care, and biotech). From 2002 through 2011, Joe was a Strategic Key Account Manager for Becton Dickinson Pharmaceutical Systems where he held responsibility for all sales and commercial development activities for large commercial pharmaceutical and biotech accounts totaling approximately $41 million in annual revenue.

Joe holds a BS in Human Ecology - Concentration in Marketing and Consumer Economics from the University of Maryland.

Crusco added, "I'm thrilled to be joining MonoSol Rx at this exciting time for the company. I believe MonoSol Rx is optimally positioned, both technologically and creatively, to capitalize on the numerous market opportunities that the PharmFilm platform offers. I'm looking forward to serving as a valuable resource to future clients and partners, and helping to share the significant value that PharmFilm provides to pharmaceutical companies that seek highly differentiated, marketable products."

About MonoSol Rx

MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® technology to develop products which address the unmet needs of patients. PharmFilm® is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs. The Company's leadership in film drug delivery is supported by strong intellectual property, a pipeline of prescription formulations based on PharmFilm® technology, and two FDA approvals - Zuplenz®, the first approved prescription oral soluble film for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting, and Suboxone® sublingual film, the first sublingual film product for the treatment of opioid dependence. For press releases and other company information visit

CONTACT: MonoSol Rx: Sanford Plachter Marketing Manager (732) 564-5000 The Ruth Group Aaron Estrada (media) (646) 536-7028 Lee Roth (investors) (646) 536-7012 lroth@theruthgroup.comSource: MonoSol Rx